We are live on ! Find out more
VYNT

Vyant Bio

Delisted

VYNT was delisted on the 12th of May, 2023.

25 hedge funds and large institutions have $9.2M invested in Vyant Bio in 2017 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

655% more capital inflows, than outflows

Capital inflows: $5.49M | Capital outflows: $727K

14% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 7

2.32% more ownership

Funds ownership: 15.64% → 17.96% (+2.3%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

4% less funds holding

Funds holding: 26 → 25 (-1)

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

Holders
25
Holders Change
-1
Holders Change %
-3.85%
% of All Funds
0.57%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
4
Increased
8
Reduced
7
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

VYNT Hedge Fund Activity: Q4 2017 in Review

25 of the 4,418 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio (VYNT) for Q4 2017, worth a combined $9.2M — up 10% from $8.35M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of VYNT and 4 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 8 added.

The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $4.54M. The largest seller was UBS Group, cutting an estimated $317K.

  • 25 institutional investors held Vyant Bio (VYNT) as of Q4 2017, down from 26 in Q3 2017.
  • Funds reported $9.2M of Vyant Bio stock for Q4 2017, up 10% quarter-over-quarter.
  • 4 funds opened new Vyant Bio positions in Q4 2017 and 6 closed out, a net change of -2 holders.
  • The largest Vyant Bio buyer in Q4 2017 was Stonepine Capital Management, an estimated $4.54M added.
  • The largest Vyant Bio seller in Q4 2017 was UBS Group, an estimated $317K sold.

Based on aggregated 13F filings for Q4 2017.